Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
INTERVENTIONAL
Inicio: 25 de nov de 2024
ID: NCT06635824
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma
INTERVENTIONAL
Inicio: 30 de ago de 2023
ID: NCT06052267
Terminado
Fase 3
ClinicalTrials.gov
A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
INTERVENTIONAL
Inicio: 30 de ago de 2021
ID: NCT04594707
Completado
Fase 2
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally
INTERVENTIONAL
Inicio: 28 de jul de 2020
ID: NCT04419506
Completado
Fase 3
ClinicalTrials.gov
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Arterial Hypertension
INTERVENTIONAL
Inicio: 19 de may de 2021
ID: NCT04732221
Completado
ClinicalTrials.gov
Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria
INTERVENTIONAL
Inicio: 15 de may de 2020
ID: NCT04383535
Completado
ClinicalTrials.gov
Psychometric Validation of the Multi-INdependency Dimensions (MIND) Score for Patients Under Prolonged Mechanical Ventilation
OBSERVATIONAL
Inicio: 1 de ago de 2014
ID: NCT02255058
Completado
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
INTERVENTIONAL
Inicio: 1 de sept de 2000
ID: NCT00268216
Completado
Fase 4
ClinicalTrials.gov
A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 5 de oct de 2016
ID: NCT02869789
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma
INTERVENTIONAL
Inicio: 1 de nov de 2009
ID: NCT01000506
Completado
Fase 3
ClinicalTrials.gov
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
INTERVENTIONAL
Inicio: 16 de abr de 2019
ID: NCT03820726
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
INTERVENTIONAL
Inicio: 1 de dic de 2015
ID: NCT02624947
Terminado
Fase 3
ClinicalTrials.gov
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
INTERVENTIONAL
Inicio: 18 de abr de 2017
ID: NCT03068130
Desconocido
ClinicalTrials.gov
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation
EXPANDED_ACCESS
ID: NCT04667234
Completado
Fase 3
ClinicalTrials.gov
The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism
INTERVENTIONAL
Inicio: 1 de jun de 2003
ID: NCT00062803
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)
INTERVENTIONAL
Inicio: 15 de dic de 2023
ID: NCT06170788
Reclutando
Fase 4
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Mucus Plugging and Other Lung Imaging Parameters in Patients With Chronic Obstructive Pulmonary Disease.
INTERVENTIONAL
Inicio: 22 de sept de 2025
ID: NCT07053423
Completado
Fase 3
ClinicalTrials.gov
A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 µg b.i.d.) as an Active Control
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00529529
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
INTERVENTIONAL
Inicio: 27 de abr de 2015
ID: NCT02414854
Completado
Fase 3
ClinicalTrials.gov
HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 25 de sept de 2009
ID: NCT01009463
Anterior
1
...
11
12
13
...
434
Siguiente
Filtros